코리아매디케어

비상장계속사업자

HYUNDAE MSO CO.,LTD

박종호

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

코리아매디케어

Business Reg. No. 3018131818 · CEO 박종호

I.Investment Overview

Target코리아매디케어 (3018131818)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명코리아매디케어
영문명HYUNDAE MSO CO.,LTD
대표자박종호
사업자등록번호3018131818
법인등록번호1543110006096
설립일1997.12.05

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW131.72021126.92022146.62023179.62024237.72025
영업이익100M KRW8.4202118.9202223202331.3202445.12025
순이익100M KRW-14.9202111.5202220.3202325.8202436.62025
Item20252024202320222021
자산총계226억원181.5억원143.2억원122.7억원121.6억원
부채총계85.6억원77.7억원65.3억원65억원75.4억원
자본총계140.4억원103.8억원77.9억원57.7억원46.2억원
매출액237.7억원179.6억원146.6억원126.9억원131.7억원
영업이익45.1억원31.3억원23억원18.9억원8.4억원
순이익36.6억원25.8억원20.3억원11.5억원-14.9억원

VI.Financial Ratios

FY2025 basis

18.96%

영업이익률

15.41%

순이익률

16.21%

ROA

26.09%

ROE

61%

부채비율

62.11%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

코리아매디케어 투심보고서 | Alpha Lenz